about
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to ExpectTowards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaUnlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancerPreclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.CD70: An emerging target in cancer immunotherapy.MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients.CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancerDeep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.A Multicenter Study to Assess Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical SettingIn vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulationCold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer CellsScreening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification MethodMass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC PatientsRadiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 StatusSpecialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical ConditionsClinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
P50
Q26775578-1C11FB31-1976-450A-A550-FB4D84147353Q33820876-B93FEB18-97E1-485A-9EE2-A3913CAE169DQ35955354-2A610602-76CF-45E0-905C-5068A9A61665Q36396832-50210EF4-6C00-437D-81C3-86A9C8872227Q38554834-CA71A1AC-B94B-4D76-A182-8CEB18E24EC2Q38619011-9B70D926-8C65-49E6-B806-AEE52C823EAEQ38850275-89F7D359-06F9-4701-A5BF-2103C143FC7DQ38858580-98CE3689-2A79-4377-9ED5-62302A18D895Q51121284-8C3C083E-2060-411A-BBF2-F4FCF005CCECQ53691994-9A164333-11D0-4643-8207-65F175DDD313Q58700168-DA6F243D-7E5F-4C42-8FD8-1B663B2B60AFQ64073233-6AA39E50-FA60-448F-9A61-B52975E311A0Q64939796-4C548FD1-6362-4460-818E-8657EDD4CF26Q64994294-15878227-A3C0-4A7A-B981-445821E1F334Q89097027-1F045E5C-F81B-4393-BFD7-AC9C4292A94BQ90850846-7E319F8D-76AD-42C1-A14E-D88B70285B68Q90944538-4A1E4834-A2D8-43E0-BA29-BE76EB7064E9Q91603736-9DDDD52B-FFE3-4F5B-8C0F-14BF3F62E1FBQ91643126-97097A4A-F915-49A1-B0EB-15C347FBBBB6Q91985777-B1AE75FC-5B06-4174-B586-5D8A59C8654DQ96603964-5443993E-E953-400A-84D1-DE64F0D31E83
P50
description
researcher ORCID ID = 0000-0003-2873-3364
@en
wetenschapper
@nl
name
Julie Jacobs
@ast
Julie Jacobs
@en
Julie Jacobs
@es
Julie Jacobs
@nl
type
label
Julie Jacobs
@ast
Julie Jacobs
@en
Julie Jacobs
@es
Julie Jacobs
@nl
prefLabel
Julie Jacobs
@ast
Julie Jacobs
@en
Julie Jacobs
@es
Julie Jacobs
@nl
P106
P1153
56683826300
P21
P31
P496
0000-0003-2873-3364